214 related articles for article (PubMed ID: 12352188)
21. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases.
Lau SK; Desrochers MJ; Luthringer DJ
Mod Pathol; 2002 May; 15(5):538-42. PubMed ID: 12011259
[TBL] [Abstract][Full Text] [Related]
22. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas.
Lüttges J; Feyerabend B; Buchelt T; Pacena M; Klöppel G
Am J Surg Pathol; 2002 Apr; 26(4):466-71. PubMed ID: 11914624
[TBL] [Abstract][Full Text] [Related]
23. Differentiation of various mucinous carcinomas.
Heatley MK
Histopathology; 2004 Jul; 45(1):87-8. PubMed ID: 15228449
[No Abstract] [Full Text] [Related]
24. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma.
Lüttges J; Zamboni G; Longnecker D; Klöppel G
Am J Surg Pathol; 2001 Jul; 25(7):942-8. PubMed ID: 11420467
[TBL] [Abstract][Full Text] [Related]
25. Necrosis in 84 ovarian carcinomas: a morphologic study of primary versus metastatic colonic carcinoma with a selective immunohistochemical analysis of cytokeratin subtypes and carcinoembryonic antigen.
DeCostanzo DC; Elias JM; Chumas JC
Int J Gynecol Pathol; 1997 Jul; 16(3):245-9. PubMed ID: 9421090
[TBL] [Abstract][Full Text] [Related]
26. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites.
Lagendijk JH; Mullink H; Van Diest PJ; Meijer GA; Meijer CJ
Hum Pathol; 1998 May; 29(5):491-7. PubMed ID: 9596273
[TBL] [Abstract][Full Text] [Related]
27. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Logani S; Oliva E; Arnell PM; Amin MB; Young RH
Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
[TBL] [Abstract][Full Text] [Related]
28. Expression of cytokeratin 7 in simultaneous mucinous tumors of the ovary and appendix.
Guerrieri C; Frånlund B; Boeryd B
Mod Pathol; 1995 Jun; 8(5):573-6. PubMed ID: 7545815
[TBL] [Abstract][Full Text] [Related]
29. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.
Nonaka D; Kusamura S; Baratti D; Casali P; Younan R; Deraco M
Histopathology; 2006 Oct; 49(4):381-7. PubMed ID: 16978201
[TBL] [Abstract][Full Text] [Related]
30. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary.
Wauters CC; Smedts F; Gerrits LG; Bosman FT; Ramaekers FC
Hum Pathol; 1995 Aug; 26(8):852-5. PubMed ID: 7543441
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women.
Ronnett BM; Shmookler BM; Diener-West M; Sugarbaker PH; Kurman RJ
Int J Gynecol Pathol; 1997 Jan; 16(1):1-9. PubMed ID: 8986525
[TBL] [Abstract][Full Text] [Related]
32. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall.
Mazziotta RM; Borczuk AC; Powell CA; Mansukhani M
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):55-60. PubMed ID: 15722794
[TBL] [Abstract][Full Text] [Related]
33. Relationship between MUC5AC and altered expression of MLH1 protein in mucinous and non-mucinous colorectal carcinomas.
Losi L; Scarselli A; Benatti P; Ponz de Leon M; Roncucci L; Pedroni M; Borghi F; Lamberti I; Rossi G; Marino M; Ponti G; Zangardi G; Menigatti M; Di Gregorio C
Pathol Res Pract; 2004; 200(5):371-7. PubMed ID: 15239345
[TBL] [Abstract][Full Text] [Related]
34. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases.
Lee KR; Young RH
Am J Surg Pathol; 2003 Mar; 27(3):281-92. PubMed ID: 12604884
[TBL] [Abstract][Full Text] [Related]
35. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.
Ferreira CR; Carvalho JP; Soares FA; Siqueira SA; Carvalho FM
Int J Gynecol Cancer; 2008; 18(1):59-65. PubMed ID: 17511804
[TBL] [Abstract][Full Text] [Related]
36. [Expression of cytokeratin 7 and 20 in ovarian metastatic carcinomas].
Dai L; Song Q; Li L; Zhong D; Hui Y
Zhonghua Bing Li Xue Za Zhi; 2001 Apr; 30(2):114-7. PubMed ID: 11866966
[TBL] [Abstract][Full Text] [Related]
37. Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma.
Shah RN; Badve S; Papreddy K; Schindler S; Laskin WB; Yeldandi AV
Hum Pathol; 2002 Sep; 33(9):915-20. PubMed ID: 12378517
[TBL] [Abstract][Full Text] [Related]
38. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
39. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
[TBL] [Abstract][Full Text] [Related]
40. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features.
McCluggage WG; Wilkinson N
Histopathology; 2005 Sep; 47(3):231-47. PubMed ID: 16115224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
